Back to the search results

Robert Bosch Krankenhaus

Auerbachstraße 110
70376 Stuttgart

Phone: 0711-8101-0
Fax: 0711-8101-3790
Mail: ed.kbr@ofni

http://www.rbk.de/

Basic information

Number of beds: 880
Number of specialist departments: 19

Number of inpatient cases: 30.234
Number of partial inpatient cases: 1.575
Number of outpatient cases: 73.730

Hospital owners: Robert Bosch Krankenhaus GmbH
Type of provider: freigemeinnützig

Academic teaching hospital

Specialist departments

Services

Quality

External comparative quality assurance

Further information

External quality assurance according to state law

Bezeichnung
Teilnahme externe Qualitätssicherung	yes
Bezeichnung
Teilnahme externe Qualitätssicherung	yes
Bezeichnung
Teilnahme externe Qualitätssicherung	yes

External quality assurance according to the DMP

Koronare Herzkrankheit (KHK)

Participation in other external comparative quality assurance procedures

Implementation of the minimum quantity agreement

Treatment area

Knee joint total endoprostheses

Quantity performed	74
Exception?	No exception

Complex interventions on the organ system esophagus for adults

Quantity performed	26
Exception?	No exception

Complex operations on the pancreatic organ system

Quantity performed	31
Exception?	No exception

Stem cell transplant

Quantity performed	61
Exception?	No exception

Minimum quantities forecast

Surgical treatment of breast cancer (mamma surgery)

Overall result forecast presentation:	yes
Quantity performed reporting year:	382
Quantity forecast year:	395
Examination by state associations?	yes
Exemption?	yes
Result of the examination by the federal state authorities?	yes
Transitional arrangement?	no

Knee joint total endoprostheses

Overall result forecast presentation:	yes
Quantity performed reporting year:	74
Quantity forecast year:	77
Examination by state associations?	yes
Exemption?	yes
Result of the examination by the federal state authorities?	yes
Transitional arrangement?	no

Complex interventions on the organ system esophagus for adults

Overall result forecast presentation:	yes
Quantity performed reporting year:	26
Quantity forecast year:	21
Examination by state associations?	yes
Exemption?	yes
Result of the examination by the federal state authorities?	yes
Transitional arrangement?	no

Complex operations on the pancreatic organ system

Overall result forecast presentation:	yes
Quantity performed reporting year:	31
Quantity forecast year:	42
Examination by state associations?	yes
Exemption?	yes
Result of the examination by the federal state authorities?	yes
Transitional arrangement?	no

Stem cell transplant

Overall result forecast presentation:	yes
Quantity performed reporting year:	61
Quantity forecast year:	77
Examination by state associations?	yes
Exemption?	yes
Result of the examination by the federal state authorities?	yes
Transitional arrangement?	no

Thoracic surgical treatment of lung cancer in adults

Overall result forecast presentation:	yes
Quantity performed reporting year:	61
Quantity forecast year:	121
Examination by state associations?	yes
Exemption?	yes
Result of the examination by the federal state authorities?	yes
Transitional arrangement?	no

Implementation of resolutions of the Federal Joint Committee on quality assurance (G-BA)

No.	Explanation
CQ24	Quality assurance measures for allogeneic stem cell transplantation for multiple myeloma (valid until 30 June 2022)
CQ25	Measures for quality assurance in the performance of minimally invasive heart valve interventions pursuant to Article 136, para. 1, sentence 1, number 2 for hospitals licensed in accordance with Article 108 of the SGB V
CQ28	Guideline on quality assurance measures for liposuction procedures for stage III lipedema (QS-RL Liposuction)
CQ27	Guideline on quality assurance measures for inpatient care with bronchoscopic lung volume reduction procedures for severe emphysema (QS Guideline bronchoscopic LVR /QS-RL BLVR)
CQ03	Quality assurance measures for the implementation of positron emission tomography (PET) in hospitals for the indications non-small-cell lung cancer (NSCLC) and solid pulmonary nodules
CQ01	Quality assurance measures for inpatient care with the indication abdominal aortic aneurysm

Compliance with staffing requirements

Clarifying chat completed: no
Clarifying chat not completed: no
No participation in clarifying chat: no
Notification of non-fulfilment of nursing care not made: no

Further training
pursuant to Article 136b, para. 1, sentence 1, no. 1 of the SGB

Number	Group
245	Medical specialists (m/f) , psychological psychotherapists (m/f) and child and adolescent psychotherapists (m/f) who are subject to the obligation to undergo further training*
156	Number of medical specialists (m/f) from no. 1 who have completed a five-year period of further training and are therefore subject to the obligation to provide evidence
124	Number of those persons from no. 2 who have provided proof of further training according to Article 3 of the G-BA regulations

* according to the “Provisions of the Joint Federal Committee for the Further Training of Medical Specialists (m/f), Psychological Psychotherapists (m/f) and Child and Adolescent Psychotherapists (m/f) in Hospitals”

General information

Protection concept against (sexual) violence against children and young people

Advice on prevention and intervention in cases of violence and abuse

According to Section 4 (2) of the Quality Management Guideline, facilities must provide for the prevention of and intervention in cases of violence and abuse as part of their internal quality management. The aim is to prevent, recognise and respond appropriately to abuse and violence, particularly against vulnerable patient groups such as children and adolescents or people in need of help, and also to prevent it within the facility. The respective procedure is aligned with the size of the facility, the range of services and the patients in order to define customised solutions for sensitising the teams as well as other suitable preventative and interventional measures. These may include information materials, contact addresses, training/education, codes of conduct, recommendations for action/intervention plans or comprehensive protection concepts.

Is a protection concept in place? Yes
No care for children and young people

Commentary on the protection concept

Gemäß § 4 Absatz 2 in Verbindung mit Teil B Abschnitt I § 1 der Qualitätsmanagement-Richtlinie haben sich Einrichtungen, die Kinder und Jugendliche versorgen, gezielt mit der Prävention von und Intervention bei (sexueller) Gewalt und Missbrauch bei Kindern und Jugendlichen zu befassen (Risiko- und Gefährdungsanalyse) und – der Größe und Organisationsform der Einrichtung entsprechend – konkrete Schritte und Maßnahmen abzuleiten (Schutzkonzept). In diesem Abschnitt geben Krankenhäuser, die Kinder und Jugendliche versorgen, an, ob sie gemäß § 4 Absatz 2 in Verbindung mit Teil B Abschnitt I § 1 der Qualitätsmanagement-Richtlinie ein Schutzkonzept gegen (sexuelle) Gewalt bei Kindern und Jugendlichen aufweisen.

Drug therapy safety

Steering committee

Drug commission

Training of employees on AMTS related topics

Availability of appropriate, topic-specific informational materials for patients on AMTS e.g. for chronic diseases, for high-risk drugs, for children

Use of standardised forms for drug medical history

Standardisierte Anamnese über das KIS (AID Klinik in iMedOne)

14.11.2019

Electronic support for the admission and anamnesis process (e.g. import of patient master data or medication plans, use of a drug knowledge database, input screen for drugs or anamnesis information)

Process description for an optimal medication process (e.g. drug anamnesis – prescription – patient information – drug delivery – drug application – documentation – therapy monitoring – result evaluation)

Ist in einer Verfahrensanweisung beschrieben

13.07.2023

SOP on good prescription practices

Dokumentenlenkungssystem

08.08.2023

Possibility of electronic prescription i.e. structured entry of active substances (or name of the preparation), form, dose, dose frequency (e.g. in the HIS, in prescription software)

Provision of one or more electronic drug information systems (e.g. Lauer-Taxe®, ifap klinikCenter®, Gelbe Liste®, Fachinfo-Service®)

Concepts for ensuring the error-free preparation of medications

Bereitstellung einer geeigneten Infrastruktur zur Sicherstellung einer fehlerfreien Zubereitung
Zubereitung durch pharmazeutisches Personal
Anwendung von gebrauchsfertigen Arzneimitteln bzw. Zubereitungen

Electronic support for the supply of patients with drugs

Vorhandensein von elektronischen Systemen zur Entscheidungsunterstützung (z.B. Meona®, Rpdoc®, AIDKlinik®, ID Medics® bzw. ID Diacos® Pharma)
Versorgung der Patientinnen und Patienten mit patientenindividuell abgepackten Arzneimitteln durch die Krankenhausapotheke (z.B. Unit-Dose-System)

Electronic documentation of the administration of drugs

Measures to minimise medication errors

Maßnahmen zur Vermeidung von Arzneimittelverwechslung
Spezielle AMTS-Visiten (z. B. pharmazeutische Visiten, antibiotic stewardship, Ernährung)
Teilnahme an einem einrichtungsübergreifenden Fehlermeldesystem (siehe Kapitel 12.2.3.2)
regelmäßige Schulungen

Measures to ensure seamless drug therapy after discharge

Aushändigung von arzneimittelbezogenen Informationen für die Weiterbehandlung und Anschlussversorgung der Patientin oder des Patienten im Rahmen eines (ggf. vorläufigen) Entlassbriefs
Aushändigung von Patienteninformationen zur Umsetzung von Therapieempfehlungen
Aushändigung des Medikationsplans
bei Bedarf Arzneimittel-Mitgabe oder Ausstellung von Entlassrezepten

Instruments and measures

The instruments and measures to promote drug therapy safety are presented with a focus on the typical procedures of the medication process in inpatient patient care. A special feature of the medication process in the inpatient environment is the transition management during admission and discharge. The instruments and measures listed below address structural elements, e.g. special IT equipment and work materials, as well as process aspects, such as work descriptions for particularly risky process steps or concepts for securing typical risk situations . In addition, proven measures to avoid or learn from medication errors can be specified. The hospital presents here which aspects it has already dealt with and which measures it has specifically implemented. The following aspects can be presented, if necessary using free text fields:
- Admission to hospital, including anamnesis
; Instruments and measures are presented for determining the old medication (drug history), the subsequent clinical assessment and the switch to the medication available in the hospital (house list), as well as for documenting both the patient's original medication and that for hospital treatment adapted medication.
- Medication process in the hospital
In this context, the following sub-processes are assumed as examples: drug history - prescription - patient information - drug delivery - drug use - documentation - therapy monitoring - result assessment. Instruments and measures for safe medication prescription can be presented, e.g. B. in terms of readability, clarity and completeness of the documentation, but also in terms of area of application, effectiveness, benefit-risk ratio, tolerability (including potential contraindications, interactions, etc.) and resource considerations. Information can also be provided to support reliable medication ordering, delivery and use or administration.
- Discharge
In particular, the measures taken by hospitals can be presented to ensure that information on drug therapy is structured and passed on to doctors and physicians providing further treatment, as well as the appropriate provision of patients with drug information, medication plans and medications. Drug prescriptions are made.

AMTS is the totality of measures to ensure an optimal medication process with the aim of reducing medication errors and thus avoidable risks for patients during drug therapy. A prerequisite for the successful implementation of these measures is that AMTS is practised as an integral part of daily routine in an interdisciplinary and multi-professional approach.

Special instrument-based equipment

Research & teaching

Job

FL01 - Lectureships / teaching posts at colleges and universities

Explanation

Medizinische Fakultät der Universität Tübingen. Medizinische und Wirtschaftswissenschaftliche Fakultäten anderer Universitäten (Baden-Württemberg, Bayern). Universität Bayreuth.

FL02 - Lectureships / teaching posts at universities of applied sciences

Explanation

Hochschule Esslingen - Fakultät für Soziale Arbeit, Gesundheit und Pflege.

FL03 - Student training (clinical traineeship / internship year)

Explanation

Akademisches Lehrkrankenhaus der Medizinischen Fakultät der Universität Tübingen. Institut für Klinische Pharmakologie Dr. Margarete Fischer-Bosch-Institut. Famulatur, praktisches Jahr, medizinische Dissertationen. Praxissemester im Rahmen von Pflegestudiengängen.

FL04 - Project-related cooperation with colleges and universities

Explanation

Bsp. Universität Tübingen, Heidelberg, Hohenheim, Bayreuth (https://www.bosch-health-campus.de/de/meldung/universitaet-bayreuth-und-bosch-health-campus-vereinbaren-forschungskooperation) und weitere.

FL05 - Participation in multi-centre Phase I/II studies

Explanation

IKP, Kardio, Hämatoloonkologie, 3PNEU, 3PNON, Nephro, Gastro

FL06 - Participation in multi-centre phase III/IV studies

Explanation

3PNEU, 3PNON, Nephro, Gastro, Gyn, Hämatoloonkologie,Kardio

FL07 - Initiation and management of uni-centric/multi-centric clinical/scientific studies

Explanation

Dr. Margarete Fischer-Bosch-Institut, Klinik für Kardiologie RBK (PI M. Schwab), Kardio, Hämatoloonkologie, 3PNEU, 3PNON, 3TCHIR, ANÄS, CHIR, Nephro, Gastro, Gyn, HerzCHIR, ZentrLab, NIM, OUCH, GERREHA, Patho

FL08 - Editors of scientific journals/textbooks

Explanation

Klinische Grundlagenwerke Innere Medizin und Nephrologie, weitere Fachbücher. Internationale Fachjournale (z.B. Pharmacogenetics &Genomics, Genome Medicine, Drug Research)

FL09 - Doctoral supervision

Explanation

Medizin und Gesundheitsökonomie Dr. rer.nat. (Institut für klinische Pharmakologie)

Training

Training in other healing professions

HB01 - Nurse and health care worker (m/f)

Comment

letzter Kurs im September 2022 abgeschlossen. Wiederholungsprüfungen laufen bis Januar 2024

HB03 - Physical therapist / physiotherapist (m/f)

Comment

Praktikumsplätze im Rahmen der schulischen Ausbildung.

HB05 - Medical technical radiology assistant (MTRA) (m/f)

Comment

a) Praktikumsplätze im Rahmen der schulischen Ausbildung. b) praktische Ausbildung im RBK, schulische Ausbildung in MTAE

HB07 - Surgical technical assistant (m/f)

Comment

Praktische Ausbildung im RBK, schulische Ausbildung an der Uniklinik Tübingen, ab Oktober 2022 schulische Ausbildung mit OTA/ATA Schule Reutlingen

HB12 - Medical technical laboratory assistant (MTLA) (m/f)

Comment

Praktikumsplätze im Rahmen der schulischen Ausbildung.

HB15 - Anaesthesia technical assistant (m/f)

Comment

Praktische Ausbildung im RBK, schulische Ausbildung an der Uniklinik Tübingen, ab Oktober 2022 schulische Ausbildung mit Schule Reutlingen

HB17 - Auxiliary nurse (m/f)

Comment

Im Rahmen einer einjährigen Ausbildung

HB10 - Midwife (m/f)

Comment

Praktikumsplätze im Rahmen der schulischen Ausbildung bzw. des Studiums.

HB06 - Occupational therapist (m/f)

Comment

Praktikumsplätze im Rahmen der schulischen Ausbildung.

HB09 - Speech therapist (m/f)

Comment

Praktikumsplätze im Rahmen der schulischen Ausbildung.

HB19 - Nursing professionals

Comment

Dreijährige generalistische Pflegeausbildung, schulische Ausbildung am eigenen Bildungszentrum; praktische Ausbildungseinsätze an allen Standorten des RBK

HB20 - Nursing professional B. Sc.